IRX-101

all catalysts(0)

nothing on the calendar yet

News(2)

• Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug
  Tarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its phase 3-stage retinal disease therapy that's being touted as a potential blockbuster.
  fiercebiotech · 9d ago
• ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
  The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
  biopharma_dive · 1mo ago